Cuba Begins Clinical Trial of New 11-Valent Pneumococcal Vaccine in Adults
• Cuba has initiated a Phase II-III clinical trial to assess the safety, immunogenicity, and efficacy of a new 11-valent pneumococcal vaccine, Quimio-Vio, in adults aged 50-74.
• The trial aims to expand the availability of pneumococcal vaccination to the adult population, addressing the high morbidity and mortality associated with pneumococcal diseases in older adults.
• The study will involve approximately 1,000 volunteers and, if successful, will lead to an application for sanitary registration to make the vaccine available nationwide.
• Previous trials of the 7-valent Quimi-Vio vaccine in children have shown a good safety profile and significant reductions in respiratory disease and invasive pneumococcal disease.
SGLT2 Inhibitors Not Cost-Effective for Type 2 Diabetes with Heart Failure in Thailand
• A cost-utility analysis in Thailand found that adding SGLT2 inhibitors to standard care for type 2 diabetes patients with heart failure is not cost-effective at current prices.
• The study suggests price reductions of up to 90% for some SGLT2 inhibitors would be needed to meet Thailand's cost-effectiveness threshold.
• The analysis, using national health data, considered direct medical and non-medical costs from a societal perspective, unlike previous studies.
• Canagliflozin showed the lowest incremental cost-effectiveness ratio, but its efficacy data relies on a post-hoc analysis with limited heart failure patients.
© Copyright 2025. All Rights Reserved by MedPath